High-dose-rate intracavitary brachytherapy for recurrent cervical cancer in the vaginal stump after hysterectomy.

Abstract

This study aimed to evaluate the treatment outcomes of patients who received high-dose-rate intracavitary brachytherapy (HDR-BT) using Iridium-192 with or without external beam radiotherapy as definitive treatment for recurrent cervical cancer after hysterectomy. Thirty-six patients with local recurrence after hysterectomy received radiotherapy including HDR-BT from 2005 to 2013. Overall survival, local control rate, and progression-free survival were estimated retrospectively via the Kaplan-Meier method. Late adverse events were also scored using the Common Terminology Criteria for Adverse Events (version 3.0). Median follow-up time was 38 (range, 7.4-101.3) months. The 3-year estimates of overall survival, local control rate, and progression-free survival were 100.0%, 82.8%, and 76.8%, respectively. Two patients (5.6%) had grade 2 lymphedema, but no other adverse events greater than grade 2 were reported. In conclusion, HDR-BT was an effective treatment modality for patients with cervical cancer recurrence in the vaginal stump.

• Authors: Yuka Kozai, Yoshiyuki Itoh, Mariko Kawamura, Rie Nakahara, Junji Ito, Tohru Okada, Fumitaka Kikkawa, Mitsuru Ikeda, Shinji Naganawa
• Journal: Nagoya journal of medical science (Nagoya J Med Sci) Vol. 81 Issue 3 Pg. 351-358 (Aug 2019) ISSN: 2186-3326 [Electronic] Japan
• PMID: 31579327 (Publication Type: Journal Article)

Chemical References

• Iridium Radioisotopes
• Iridium-192

Topics

• Adult
• Aged
• Aged, 80 and over
• Brachytherapy (methods)
• Disease-Free Survival
• Female
• Humans
• Iridium Radioisotopes (therapeutic use)
• Middle Aged
• Neoplasm Recurrence, Local
• Retrospective Studies
• Treatment Outcome
• Uterine Cervical Neoplasms (radiotherapy)
• Vagina (pathology)